<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4675">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01653002</url>
  </required_header>
  <id_info>
    <org_study_id>RLK-Epi-1</org_study_id>
    <secondary_id>11-4921-BO</secondary_id>
    <nct_id>NCT01653002</nct_id>
  </id_info>
  <brief_title>Methylation Level of SHOX2 in Endobronchial Ultrasound With Real-time Guided Transbronchial Needle Aspiration for Lung Cancer Staging</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Epigenomics, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A DNA hypermethylation of the gene locus SHOX2 can be frequently found in lung cancer
      tissue. The purpose of this study is to determine whether the assessment of the
      hypermethylation level of SHOX2 in specimens obtained by endosonographic guided bronchoscopy
      makes a contribution to lung cancer staging.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Diagnostic Performance of SHOX2</measure>
    <time_frame>one Year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diagnostic performance of SHOX2 methylation Level as biomarker for lung cancer compared to histologic evaluation of EBUS-TBNA specimen alone.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lung Cancer With Mediastinal Lymph Node Involvement</condition>
  <arm_group>
    <arm_group_label>Lung cancer with lymph node involvement</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>Lung cancer with lymph node involvement</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with proven or suspcted lung cancer and enlarged mediastinal or hilar lymph nodes
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of lung cancer

          -  enlarged mediastinal or hilar lymph nodes (&gt;10 mm)

        Exclusion Criteria:

          -  clinical condition which excludes general anesthesia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kaid Darwiche, MD</last_name>
    <phone>+49201433</phone>
    <phone_ext>4219</phone_ext>
    <email>kaid.darwiche@ruhrlandklinik.uk-essen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruhrlandklinik - Universit√§tsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaid Darwiche, MD</last_name>
      <phone>+49201433</phone>
      <phone_ext>4219</phone_ext>
      <email>kaid.darwiche@ruhrlandklinik.uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Kaid Darwiche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lutz Freitag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>July 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Kaid Darwiche</investigator_full_name>
    <investigator_title>Dr. med. Kaid Darwiche</investigator_title>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>EBUS-TBNA</keyword>
  <keyword>Epigenetics</keyword>
  <keyword>shox2 protein, human</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
